References
- Mundy GR, Guise Ta. Hormonal control of calcium homeostasis. Clin Chem 1999;45:1347-52.
- Ravi C, Assunta A, Disorders of calcium homeostasis. In; Elzouki AY,Harfi HA, Nazer H, William OH, Stapleton FB, Whitley RJ, editors, Textbook of Clinical Pediatrics. 2nd ed. NewYork: Springer, 2012; 3611-6.
- Makras P, Papapoulos SE. Medical treatment of hypercalcaemia. Hormones 2009;8:83-95. https://doi.org/10.14310/horm.2002.1225
- Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373-9. https://doi.org/10.1056/NEJMcp042806
- Rosner MH, Dalkin AC. Onco-nephrology: The pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol 2012;7:1722-9. https://doi.org/10.2215/CJN.02470312
- Shu ST, Dirksen WP, Weibaecher KN, Rosol TJ. Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma. In; olga B, Sinia D, kimberly JP, editors. T-cell Leukemia. 3rd ed. Croatia: InTech, 2002;181-94.
- McKay C, Furman WL. Hypercalcemia complicating childhood malignancies. Cancer 1993;72:256-60. https://doi.org/10.1002/1097-0142(19930701)72:1<256::AID-CNCR2820720145>3.0.CO;2-D
- Takami H. Hypercalcemic crisis. Textb Endocr Surg 2005:543-8.
- Hasler U, Leroy V, Martin PY, Feraille E. Aquaporin-2 abundance in the renal collecting duct: new insights from cultured cell models. AJP Ren Physiol 2009;297:F10-8. https://doi.org/10.1152/ajprenal.00053.2009
- Riccardi D, Brown EM. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Ren Physiol 2010;298:F485-99. https://doi.org/10.1152/ajprenal.00608.2009
- Argiles a, Kerr PG, Canaud BJM, Flavier JL, Charles Mion. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993;43:630-40. https://doi.org/10.1038/ki.1993.92
- Wisneski LA, Croom WP, Silva OL, Becker KL. Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 1978;24:219-22. https://doi.org/10.1002/cpt1978242219
- Davies JH, Shaw NJ. Investigation and management of hypercalcaemia in children. Arch Dis Child 2012;97:533-8. https://doi.org/10.1136/archdischild-2011-301284
- Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78. https://doi.org/10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
- Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009;4:221-33. https://doi.org/10.2215/CJN.02550508
Cited by
- Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges vol.27, pp.26, 2017, https://doi.org/10.3748/wjg.v27.i26.4104